Horizon Pharma Inc (HZNP) 17.06 $HZNP Here's Why Horizon

New Post Public Reply Private Reply Replies (0) Message Board

Oct 23, 2015 at 7:46 PM

Horizon Pharma Inc (HZNP) 17.06 $HZNP

Here's Why Horizon Pharma Plc Is Soaring Today
George Budwell, The Motley Fool - Motley Fool - Fri Oct 23, 12:57PM CDT
What : Shares of Horizon Pharma plc , a specialty biopharmaceutical company, climbed by over 30% today on heavy volume. This rally was catalyzed by a public letter from the company rebuking a New York Times article that suggested that Horizon was...
ESRX: 85.11 (+2.42), HZNP: 17.06 (+3.94)

Horizon Pharma Counters Depomed Hit On Drug Pricing
at Investor's Business Daily - Fri Oct 23, 10:47AM CDT
Specialty drugmaker Horizon Pharma's (HZNP) battered stock rose sharply Friday as the company issued a statement countering its takeover target Depomed 's (DEPO) charges regarding its drug-pricing policy. Horizon has been in hot water since Monday,...
ESRX: 85.11 (+2.42), VRX: 116.16 (+6.29), HZNP: 17.06 (+3.94), CVS: 103.95 (-0.34), DEPO: 16.94 (+1.53)

Horizon Pharma plc Corrects Misinformation in the Marketplace
Marketwired - Thu Oct 22, 4:39PM CDT
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today provided the following statement to correct misinformation in the marketplace:
HZNP: 17.06 (+3.94)

INVESTOR NOTICE: Khang & Khang LLP Announces An Investigation Of Claims Against Horizon Pharma plc And Advises Shareholders To Contact The Firm
Business Wire - Thu Oct 22, 9:30AM CDT
Khang & Khang LLP announces that it is investigating claims of potential misrepresentations by Horizon Pharma plc ("Horizon" or the "Company"

(NASDAQ: HZNP). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
HZNP: 17.06 (+3.94)

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Horizon Pharma plc
PR Newswire - Thu Oct 22, 9:00AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Horizon Pharma plc ("Horizon" or the "Company"

(NasdaqGS: HZNP -News). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484.
HZNP: 17.06 (+3.94)

Covered Call Alerts For Chipotle Mexican Grill, Horizon Pharma, Abbott Laboratories, Bank of America and Amgen Released By InvestorsObserver
PR Newswire - Thu Oct 22, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CMG, HZNP, ABT, BAC and AMGN.
ABT: 43.60 (+0.10), CMG: 649.72 (-0.90), HZNP: 17.06 (+3.94), AMGN: 155.75 (+3.44), BAC: 16.52 (+0.36)

Depomed Comments on Recent Reports Regarding Horizon Pharma's Business Model
PR Newswire - Thu Oct 22, 7:30AM CDT
Depomed, Inc. (NASDAQ: DEPO) ("Depomed" or the "Company"

today issued the following statement in response to numerous recent reports surrounding Horizon Pharma plc's (NASDAQ: HZNP) ("Horizon"

business model, in particular concerns raised about aggressive drug pricing practices and Horizon's use of specialty pharmacies:
HZNP: 17.06 (+3.94), DEPO: 16.94 (+1.53)

Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering PENNSAID(R) (diclofenac sodium topical solution) 2%
Marketwired - Thu Oct 22, 6:00AM CDT
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. patent application number 14/705,649 (U.S. publication number 2015-0231264), entitled "Diclofenac Topical Formulation" that covers Horizon's U.S. approved product PENNSAID(R) (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%).
HZNP: 17.06 (+3.94)

Horizon Pharma plc Provides Update on Relationship With Specialty Pharmacies
Marketwired - Wed Oct 21, 4:55PM CDT
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today provided an update on its relationship with specialty pharmacies:
HZNP: 17.06 (+3.94)

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Horizon Pharma plc - HZNP
ACCESSWIRE - Wed Oct 21, 4:46PM CDT
NEW YORK, NY / ACCESSWIRE / October 21, 2015 / Pomerantz LLP is investigating claims on behalf of investors of Horizon Pharma plc ("Horizon" or the "Company"

(NASDAQ: HZNP). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
HZNP: 17.06 (+3.94)

IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces An Investigation Of Claims Against Horizon Pharma plc And Encourages Investors To Contact The Firm
Business Wire - Wed Oct 21, 2:40PM CDT
Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by Horizon Pharma plc ("Horizon" or the "Company"

(NASDAQ: HZNP). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
HZNP: 17.06 (+3.94)

Horizon Pharmaceutical (HZNP) Stock Tumbles on Use of Specialty Pharmacies
at The Street - Wed Oct 21, 1:27PM CDT
Horizon Pharmaceutical (HZNP) stock is declining in afternoon trading, as it and Valeant Pharmaceuticals are scrutinized for their use of specialty pharmacies.
HZNP: 17.06 (+3.94)

INVESTIGATION ALERT: Rigrodsky & Long, P.A. Announces Commencement of an Investigation of Horizon Pharma plc for Possible Violations of Federal Securities Laws
PR Newswire - Wed Oct 21, 1:06PM CDT
Rigrodsky & Long, P.A.:
HZNP: 17.06 (+3.94)

Targets of Market Hatred Can Change Daily
at The Street - Wed Oct 21, 12:03PM CDT
It used to be industrials, now it's health care.
TSLA: 209.09 (-2.63), VRX: 116.16 (+6.29), GE: 29.51 (-0.07), CLX: 123.25 (-0.35), VMW: 58.18 (+1.39), NKE: 130.53 (-1.88), HON: 103.13 (+0.55), UTX: 100.62 (+0.83), WMT: 58.30 (-0.60), INTC: 34.90 (+0.50), SLB: 78.35 (+0.09), K: 71.70 (-0.31), SBUX: 62.61 (+1.12), CMG: 649.72 (-0.90), HZNP: 17.06 (+3.94), COST: 155.74 (-2.41), EMC: 26.10 (+0.32), CRZO: 37.51 (-0.72), PPG: 103.99 (+0.37), BHI: 53.93 (-1.66), ETN: 54.31 (-0.04), SWKS: 82.55 (+0.86), HAL: 39.21 (-0.50), HRL: 68.33 (-0.16), NXPI: 96.09 (-1.86), BA: 146.70 (+0.39), WDC: 69.34 (-0.62), NFLX: 100.04 (+2.72), LB: 93.88 (-2.88), LRCX: 74.57 (+1.96), GM: 35.95 (+0.53), MCD: 112.59 (+1.72), DOV: 64.44 (+0.44), KLAC: 65.35 (+0.45), AVGO: 129.58 (+4.24), SNDK: 78.37 (+1.28)

Horizon Pharma plc Announces Favorable Markman Ruling in RAVICTI(R) (glycerol phenylbutyrate) Oral Liquid Patent Infringement Lawsuit
Marketwired - Wed Oct 21, 6:00AM CDT
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that a favorable Markman ruling has been issued by Judge Roy Payne in the United States District Court for the Eastern District of Texas Marshall Division in the patent infringement lawsuit filed by Horizon against Par Pharmaceutical, Inc. for an Abbreviated New Drug Application ("ANDA"

to market a generic version of RAVICTI.
HZNP: 17.06 (+3.94)

HZNP SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by Horizon Pharma plc and Certain Officers and Directors
Business Wire - Tue Oct 20, 3:39PM CDT
Levi & Korsinsky, LLP announces that it has commenced an investigation of Horizon Pharma plc ("Horizon Pharma" or the "Company"

(NASDAQGS:HZNP) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.
HZNP: 17.06 (+3.94)

Jim Cramer -- Microsoft, IBM Should Have Their Eyes on the Buys
at The Street - Tue Oct 20, 1:20PM CDT
If you ask Jim Cramer (and social media users did), Microsoft should acquire Salesforce, IBM should grab Box, pharmaceuticals have a political problem, and there's no substitute for Berkshire Hathaway.
WFM: 32.28 (-0.25), VRX: 116.16 (+6.29), BOX: 12.96 (+0.26), TREE: 98.00 (+3.38), TFM: 25.18 (-0.07), PSTG: 19.27 (-0.22), WFC: 54.75 (+0.69), MKL: 875.96 (+7.04), WWAV: 40.75 (-0.26), RDUS: 64.89 (+3.80), LEN: 52.12 (+0.28), IBM: 144.68 (+0.59), HZNP: 17.06 (+3.94), WY: 30.03 (+0.02), MSFT: 52.87 (+4.84), TOL: 36.78 (+0.34), BRK.A: 206,584.00 (+564.00), CRM: 78.56 (+1.19)

Horizon Pharma plc to Host Third Quarter 2015 Conference Call and Webcast on November 6, 2015
Marketwired - Fri Oct 16, 6:00AM CDT
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced today that its third quarter 2015 financial results will be released on Friday, November 6, 2015. Following the announcement, Horizon's management will host a live conference call and webcast at 8 a.m. Eastern Time to review the Company's financial and operating results.
HZNP: 17.06 (+3.94)

Horizon Pharma plc Files Definitive Proxy Statement for Extraordinary General Meeting of Horizon Pharma Shareholders
Marketwired - Thu Oct 15, 6:01AM CDT
Horizon Pharma plc (NASDAQ: HZNP) ("Horizon Pharma"

, a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that it has filed a definitive proxy statement on Schedule 14A with the Securities and Exchange Commission ("SEC"

in connection with the extraordinary general meeting of Horizon Pharma shareholders (the "Meeting"

. The principal purpose of the Meeting is to approve the issuance of Horizon ordinary shares in connection with Horizon Pharma's proposed acquisition of Depomed, Inc.
HZNP: 17.06 (+3.94), DEPO: 16.94 (+1.53)

Three Canadian Biotechs with Pending Catalysts
ACCESSWIRE - Wed Oct 14, 11:02AM CDT
CORAL GABLES, FL / ACCESSWIRE / October 14, 2015 / In the rush of sector-wide biotech news, especially since Hillary Clinton's now infamous tweet that rocked the entire sector late last month, some developments that would have otherwise been big news may have gotten a bit lost in the ruckus. This is even more the case with foreign stocks that already receive less focus than US-based biotechs. Lest we lose sight of potential opportunities, here are three Canadian biotechs with catalysts pending.
HZNP: 17.06 (+3.94), TRIL: 14.28 (-0.01)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hyperliquid Expands Stock Buyback to $100 Million

Diving Into Hyperliquid's $100 Million Bold Move Let’s cut through the corporate fluff—Hyperliquid Strategies Inc. just cranked up their stock repurchase program to a cool $100 million. Yep, that’s right—the brain trust behind NASDAQ:PURR has pulled out the checkbook to buy more of its own shares. This decision, unveiled on October 23, 2026, is like tossing a...

Think Together Marks 20 Years of ASES Impact in CA

Hands-on Learning: California's Bright Future Starts Here Who's ever thought a schoolyard's the same after three? Let me tell you, in California, it's staying alive and kicking, thanks to Think Together's whirlwind of celebrations for the After School Education and Safety (ASES) program. We're talking 450 schoolyard shindigs highlighting not just how far expanded learning...

Home Insurance Gaps: Risky Assumptions Uncovered

Unseen Threats to Homeownership Safety Liability gaps in insurance are like those stubborn stains on the carpet you keep missing—nearly invisible until you're flat on your face. In Alpharetta and Fulton County, homes aren't as secure from financial pitfalls as their charming façades suggest. So, what's the danger that folks are glossing over here? Hidden Dangers of...

Gemmy's Orchestra of Lights Op. 2 Unveils New Show

Jazzing Up the Holidays with Gemmy's Latest Innovation Just when you thought holiday displays couldn't get more extravagant, along comes Gemmy with its latest wonder—the Orchestra of Lights™ Op. 2. Exclusively hitting Lowe's shelves, this isn't your average set of twinkling bulbs. It's an all-out sensory assault, mixing tunes straight out of yuletide hit lists with...

Chemours Faces Class Action Over Fraud Allegations

Chemours and the Aftermarket Mirage When it rains, it pours, and for Chemours, the forecast isn't looking sunny. Investors are gearing up to slap Chemours Company (NYSE: CC) with a securities fraud class action. Why, you ask? Overstatement of aftermarket demand for refrigerants left investors high and dry after stock prices took an 18% nosedive. On August 4, 2026,...

Northern Virginia's Housing Inventory Surges Despite Market Pressures

Unexpected Surge in Northern Virginia's Inventory Walking around Fairfax these days, you might feel like you're in a time warp, especially if you're tracking the housing market. See, while the rest of the country's housing market groans under sluggish sales and creeping prices, Northern Virginia's doing a dance of its own. Inventory's ballooning faster than a parade...

Civista Welcomes Healthcare Leader to Boost Growth

Expanding the Boardroom with Healthcare Expertise In an unexpected twist for Civista Bancshares (NASDAQ: CIVB), the financial holding company is roping in some healthcare brass to its board. Jeremy Normington-Slay just snagged a seat at Civista's table, and he's bringing his tough-sledding healthcare leadership chops straight from Firelands Health. A $4.3 billion outfit...

Bio-Thera's New Data: A Game Changer for NSCLC?

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...

Understanding New Jersey's Gun Laws Through Legal Eyes

Cracking New Jersey's Complex Legal Code You ever try to decode the rulebook judges play by when gun possession and aggravated assault enter the picture in New Jersey? Well, it's as tricky as picking a safe with a wet noodle. Thankfully, a legal eagle named Ed Weinstock sheds some light on this murky terrain. Now, this isn't just some academic exercise—it's a look into...

mF International Shuts Down Legacy Business to Focus on BCH

mF International's Bold Digital Leap It’s a big move in the financial landscape when a firm decides to shake things up and pivot hard towards the digital frontier. mF International Limited (NASDAQ:MFI) is shutting the door on its legacy financial trading solutions and dedicating itself entirely to the budding world of digital assets. This isn’t just another facelift;...